A multicenter study of niraparib as maintenance therapy in BRCA wild-type, newly diagnosed advanced ovarian cancer (Polo trial)

被引：0

作者：

Kim, Se Ik ^{[1
]}

Choi, Chel Hun ^{[2
]}

Kim, Ji Hyun ^{[3
,4
]}

Lee, Yong Jae ^{[5
]}

Park, Jeong-Yeol ^{[6
]}

Suh, Dong Hoon ^{[7
]}

Kim, Yong Beom ^{[7
]}

Lee, Jung-Yun ^{[5
]}

Lim, Myong Cheol ^{[3
,4
]}

Kim, Byoung Gie ^{[2
]}

Kim, Jae-Weon ^{[1
]}

机构：

[1] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea

[2] Sungkyunkwan Univ, Dept Obstet & Gynecol, Sch Med, Samsung Med Ctr, Seoul, South Korea

[3] Natl Canc Ctr, Ctr Gynecol Canc, Goyang Si, South Korea

[4] Ctr Clin Trial, Goyang Si, South Korea

[5] Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Seoul, South Korea

[6] Asan Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea

[7] Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, Seongnam Si, South Korea

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.476

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TP016

引用

页码：A252 / A252

页数：1

共 50 条

[21] Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
Shona Nag
Shyam Aggarwal
Amit Rauthan
Narayanankutty Warrier
Journal of Ovarian Research, 15
[22] Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)
Gonzalez Martin, A.
Pothuri, B.
Vergote, I. B.
Christensen, R. D.
Graybill, W.
Mirza, M. R.
McCormick, C.
Lorusso, D.
Hoskins, P.
Freyer, G.
Backes, F.
Baumann, K.
Redondo, A.
Moore, R. G.
Vulsteke, C.
O'Cearbhaill, R. E.
Lund, B.
Li, Y.
Gupta, D.
Monk, B. J.
ANNALS OF ONCOLOGY, 2019, 30 : 893 - 893
[23] Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
Arnold Lee
Targeted Oncology, 2021, 16 : 839 - 845
[24] Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Li, J.
Mei, B.
Mei, H. J.
He, S.
Zhu, Y.
Huang, J.
Wang, D.
Zhang, G.
ANNALS OF ONCOLOGY, 2022, 33 : S1508 - S1508
[25] PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis
Lin, Q.
Liu, W.
Xu, S.
Shang, H.
Li, J.
Guo, Y.
Tong, J.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (03) : 485 - 493
[26] Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
Lee, Arnold
TARGETED ONCOLOGY, 2021, 16 (06) : 839 - 845
[27] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Colombo, Nicoletta
Moore, Kathleen
Scambia, Giovanni
Oaknin, Ana
Friedlander, Michael
Lisyanskaya, Alla
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Banerjee, Susana
Oza, Amit
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William H.
Kim, Jae-Weon
Mathews, Cara
Liu, Joyce
Lowe, Elizabeth S.
Bloomfield, Ralph
DiSilvestro, Paul
GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 41 - 49
[28] Real-world overall survival in second-line maintenance niraparib monotherapy versus active surveillance in patients with BRCA wild-type recurrent ovarian cancer
Coleman, Robert L.
Perhanidis, Jessica A.
Kalilani, Linda
Zimmerman, Nicole M.
Golembesky, Amanda
Moore, Kathleen N.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[29] Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer
Coleman, Robert L.
Perhanidis, Jessica
Kalilani, Linda
Zimmerman, Nicole M.
Golembesky, Amanda
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Addition of Durvalumab and Olaparib to Standard Treatment Improves PFS in BRCA Wild-Type Advanced Ovarian Cancer
Coleman, Robert L.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 362 - 363

← 1 2 3 4 5 →